(Q43837751)

27 November 2017

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme (English)

1 reference

27 November 2017

0 references

1 reference

G M Marx

1

1 reference

27 November 2017

N Pavlakis

2

1 reference

27 November 2017

S McCowatt

3

1 reference

27 November 2017

F M Boyle

4

1 reference

27 November 2017

J A Levi

5

1 reference

27 November 2017

D R Bell

6

1 reference

27 November 2017

R Cook

7

1 reference

27 November 2017

M Biggs

8

1 reference

27 November 2017

N Little

9

1 reference

27 November 2017

H R Wheeler

10

1 reference

27 November 2017

1 August 2001

1 reference

Journal of Neuro-Oncology

27 November 2017

1 reference

27 November 2017

54

1 reference

27 November 2017

31-38

1 reference

27 November 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1012554328801

27 November 2017

0 references

cites work

Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation

1 reference

12 December 2020

Adjuvant and neoadjuvant treatment for primary brain tumors in adults

1 reference

12 December 2020

Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas.

1 reference

12 December 2020

Thalidomide in Oncology: The Peril and the Promise

1 reference

12 December 2020

Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients.

1 reference

12 December 2020

Estimates of the worldwide incidence of 25 major cancers in 1990.

1 reference

12 December 2020

Thalidomide-induced neuropathy and genetic differences in drug metabolism

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?

1 reference

12 December 2020

Correlation of measurements of pressure perception using the pressure-specified sensory device with electrodiagnostic testing

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease.

1 reference

12 December 2020

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

12 December 2020

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?

1 reference

12 December 2020

MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation.

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

12 December 2020

Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies

1 reference

12 December 2020

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

1 reference

12 December 2020

Estimates of the worldwide mortality from 25 cancers in 1990.

1 reference

12 December 2020

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

12 December 2020

Chemotherapy-induced peripheral neuropathy

1 reference

12 December 2020

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1012554328801

1 reference

Dimensions Publication ID

27 November 2017

0 references

1 reference